AMACR Antibody

• Elevated AMACR expression has been identified as a significant adverse prognostic indicator and a potential therapeutic target in oral squamous cell carcinoma. PMID: 29725255
• Studies have investigated AMACR expression in normal colonic mucosa, adenomas with varying degrees of dysplasia, colonic carcinomas, lymph node metastases, and liver metastases of colonic carcinomas. AMACR expression is nearly absent in normal mucosa but increases in both adenomas and carcinomas. Expression decreases in lymph node metastases but is significantly elevated in liver metastases. PMID: 29179959
• IMP3, another enzyme, exhibits similar specificity to AMACR but demonstrates superior sensitivity, intensity, and extent of reactivity. Therefore, IMP3 can serve as an alternative to AMACR in supporting the diagnosis of Barrett's esophagus (BE)-dysplasia and esophageal adenocarcinoma (EAC). PMID: 26766126
• AMACR and high molecular weight cytokeratin (HMWCK) are valuable adjuncts to biopsy for resolving diagnostically challenging cases. PMID: 28508828
• A single nucleotide polymorphism (SNP) within the AMACR gene has been linked to schizophrenia risk loci, potentially impacting neurocognitive performance. PMID: 28902459
• Research indicates that AMACR expression is significantly elevated in patients with prostate cancer. PMID: 29277318
• High AMACR expression is associated with prostate cancer. PMID: 28741117
• Immunohistochemical staining revealed positive AMACR expression in 86 out of 108 prostate carcinoma cases, while the remaining 12 cases showed complete absence of AMACR. PMID: 28384107
• Data suggest a significant correlation between Alpha-methylacyl-CoA racemase (AMACR) and ERG protein expression, with prognostic implications in prostate cancer. PMID: 27271990
• AMACR is expressed in a majority of chordomas but only in a minority of chondrosarcomas. AMACR can serve as an immunohistochemical (IHC) marker for chordoma, offering differentiating capability comparable to that of beta-catenin. PMID: 26888362
• AMACR transcripts were detected in all radical prostatectomy (RP)-prostate cancer and RP-benign samples, but not in non-cancerous cystoprostatectomy samples. This suggests a global increase in AMACR expression within cancerous prostates. PMID: 26928323
• AMACR was not found to be regulated in the white blood cells of multiple sclerosis patients. PMID: 26648339
• Research has shown that 34betaE12 is the most suitable negative marker to use in conjunction with alpha-methylacyl coenzyme A racemase (AMACR) as a positive marker for diagnosing prostate adenocarcinoma. PMID: 20189848
• Polymorphisms within the AMACR gene, D175G and M9V, have been linked to prostate cancer. The S201L polymorphism may also be associated with prostate cancer risk. However, no association was observed between the K277E or Q239H polymorphisms and prostate cancer susceptibility. PMID: 25773837
• AMACR amplification is a mechanism that drives increased mRNA and protein expression, contributing to tumor aggressiveness through heightened cell proliferation in gastrointestinal stromal tumors. PMID: 25473890
• In the diagnosis of ovarian clear cell carcinoma, AMACR demonstrates high specificity but suboptimal sensitivity. PMID: 25551297
• AMACR overexpression in myxofibrosarcomas can be driven by amplification, is associated with tumor aggressiveness, and may hold relevance as a druggable target. PMID: 25384383
• The combination of p63 and AMACR offers significant additional value in addressing morphologically suspicious cases and should be considered on a case-by-case basis, particularly in prostatic needle biopsies and small focal lesions. PMID: 25313761
• Findings suggest AMACR as a potentially useful immunohistochemical marker for differentiating malignant melanomas and dysplastic nevi from conventional melanocytic nevi. PMID: 25149154
• AMACR may serve as a potential prognostic marker for predicting early recurrence or metastasis of hepatocellular carcinoma following hepatectomy. PMID: 25092674
• The overexpression of AMACR in prostate cancer was not found to be associated with dietary influences on phytanic acid. PMID: 25307752
• Overexpressed AMACR has been identified as a significant prognostic factor and a potential therapeutic target for future research. PMID: 24833092
• AMACR is a valuable immunohistochemical marker for the differential diagnosis of solid pseudopapillary neoplasms of the pancreas. PMID: 24675392
• AMACR should be considered the primary positive marker for confirming a diagnosis of minimal adenocarcinoma of the prostate. PMID: 24705308
• Genetic variations in AMACR have been linked to the risk of sporadic prostate cancer that underwent radical prostatectomy in Korean patients. PMID: 24383053
• Strong AMACR expression is associated with an increased risk of neoplastic progression in Barrett's esophagus. PMID: 24004067
• Within the subgroup of papillary renal cell carcinoma, both a higher grade and the presence of distant metastases were associated with a lower percentage of alpha-methylacyl CoA racemase (AMACR) expressing tumors. PMID: 22009118
• AMACR's role in drug metabolism, cancer, and drug design has been investigated. PMID: 23376124
• A case report describes an AMACR homozygous mutation responsible for adult-onset alpha-methyl-acyl-CoA racemase deficiency. PMID: 20821052
• These findings indicate that AMACR expression is strongly associated with endometrial clear cell carcinoma and exhibits relatively robust diagnostic test performance. PMID: 24119561
• Overall disease-free survival tended to be worse in AMACR-positive patients, and in the adenocarcinoma subgroup, it was significantly shorter. PMID: 23235347
• ERG immunohistochemistry could be considered as a second round of immunostaining for select challenging cases of foamy gland carcinoma of the prostate with low AMACR expression. PMID: 23797726
• Cases of clear cell renal carcinoma exhibited immunoreactivity for alpha-methylacyl-CoA racemase and strong diffuse immunopositivity for cytokeratin. PMID: 23434146
• Alpha-methylacyl-CoA racemase cannot differentiate hepatocellular carcinoma from liver cell dysplasia, although it can distinguish both from nondysplastic lesions. PMID: 22542076
• The sensitivity and specificity of AMACR for diagnosing prostate adenocarcinoma and benign glands in Japanese patients are lower than those previously reported in Western countries. PMID: 22593005
• Research suggests that alpha-methylacyl-coenzyme A racemase is a valuable marker for distinguishing between grade 1 and grade 2 neuroendocrine tumors, and neuroendocrine carcinoma of the stomach. PMID: 22782380
• High AMACR expression is associated with prostate cancer. PMID: 22248277
• Alpha-methylacyl-coenzyme A racemase expression is associated with mucin phenotypes of gastric neoplasia, particularly with the expression of CDX2 and MUC5AC. PMID: 22078291
• AMACR is considered a more accurate marker than PTOV1 in identifying high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer. PMID: 22507319
• Our study demonstrated that 34betaE12 is the most appropriate negative marker to combine with AMACR as a positive marker for the diagnosis of prostate adenocarcinoma. PMID: 20189848
• This report presents the first high-throughput screen for discovering novel AMACR inhibitors, characterizes the first non-substrate-based inhibitors, and validates AMACR as a viable chemotherapeutic target in vitro. PMID: 21441411
• Overexpression of alpha-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas. PMID: 21457159
• A combination of high molecular weight cytokeratin and alpha-methylacyl CoA racemase is highly valuable in addressing morphologically suspicious cases and significantly enhancing diagnostic accuracy in prostate cancer. PMID: 21176184
• Findings suggest that AMACR may play a significant role in susceptibility to schizophrenia in male patients. PMID: 20875727
• Our data suggest that AMACR variants have better discriminatory power than total AMACR in distinguishing between prostate cancer (CaP) and adjacent normal tissue. These findings may be useful for developing future diagnostic assays. PMID: 21195844
• Examine P504S expressing circulating prostate cells as a marker for prostate cancer. PMID: 20664974
• AMACR shows promise as a marker to indicate indefinite dysplasia in Barrett's esophagus. PMID: 20636793
• Results describe alpha-methylacyl CoA racemase (AMACR) expression in relation to various dysplasia phenotypes and clinicopathological parameters of sporadic colorectal adenomas. PMID: 20503447
• Marker of differential diagnosis of kidney cancer. PMID: 20102405
• The expression of AMACR is increased in benign sebaceous glands and sebaceous hyperplasia, with decreasing AMACR expression in tumors with less sebaceous differentiation. PMID: 19638170

Show More

Hide All

HGNC: 451

OMIM: 214950

KEGG: hsa:23600

STRING: 9606.ENSP00000371517

UniGene: Hs.508343